Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Biomaterials. 2022 Jul;286:121604. doi: 10.1016/j.biomaterials.2022.121604. Epub 2022 May 25.
Tissue engineering strategies for treating bone loss to date have largely focused on targeting stem cells or vascularization. Immune cells, including macrophages and T cells, can also indirectly enhance bone healing via cytokine secretion to interact with other bone niche cells. Bone niche cues and local immune environment vary depending on anatomical location, size of defects and disease types. As such, it is critical to evaluate the role of the immune system in the context of specific bone niche and different disease types. This review focuses on immunomodulation research for bone applications using biomaterials and cell-based strategies, with a unique perspective from different disease types. We first reviewed applications for prolonging orthopaedic implant lifetime and enhancing fracture healing, two clinical challenges where immunomodulatory strategies were initially developed for orthopedic applications. We then reviewed recent research progress in harnessing immunomodulatory strategies for regenerating critical-sized, long bone or cranial bone defects, and treating osteolytic bone diseases. Remaining gaps in knowledge, future directions and opportunities were also discussed.
迄今为止,用于治疗骨丢失的组织工程策略主要集中在靶向干细胞或血管生成上。免疫细胞,包括巨噬细胞和 T 细胞,也可以通过细胞因子分泌间接增强骨愈合,从而与其他骨龛细胞相互作用。骨龛线索和局部免疫环境取决于解剖位置、缺陷大小和疾病类型。因此,评估免疫系统在特定骨龛和不同疾病类型中的作用至关重要。本综述重点关注使用生物材料和基于细胞的策略进行骨应用的免疫调节研究,从不同疾病类型的独特视角进行探讨。我们首先回顾了用于延长骨科植入物寿命和增强骨折愈合的应用,这是最初为骨科应用开发免疫调节策略的两个临床挑战。然后,我们回顾了利用免疫调节策略再生临界尺寸长骨或颅骨缺损以及治疗溶骨性骨疾病的最新研究进展。还讨论了知识的剩余差距、未来的方向和机会。